Active, not recruitingPhase 3NCT06294678
Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies
Studying Graft versus host disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Anhui Provincial Hospital
- Principal Investigator
- Xiaoyu Zhu, ph.DThe First Affiliated Hospital of USTC (Anhui Provincial Hospital)
- Intervention
- Time of stem cell infusion(procedure)
- Enrollment
- 198 target
- Eligibility
- 12-60 years · All sexes
- Timeline
- 2024 – 2026
Study locations (6)
- The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
- Peking University First Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
- Rui Jin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, Shanghai Municipality, China
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06294678 on ClinicalTrials.govOther trials for Graft versus host disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07166848Electrostimulation Study for Ocular Graft vs. Host DiseaseZhonghui K. Luo, MD, PhD
- RECRUITINGPHASE2NCT07246031BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell TransplantationBioPhoenix Co., Ltd.
- RECRUITINGNANCT07184853Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHDFirst Affiliated Hospital of Zhejiang University
- RECRUITINGPHASE2NCT07118254A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CROSSOVER STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 μG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD)Lubris Bio Pty Ltd
- RECRUITINGPHASE4NCT06824103Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host DiseaseNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT07047456Effect of Stem Cell Infusion Time on aGVHD in Patients With Hematological Malignancies Post UCBTAnhui Provincial Hospital
- RECRUITINGPHASE2NCT06799195Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell TransplantationUniversity of Nebraska
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT07162688Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.Fujian Medical University